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Abstract
Transfusion-related acute lung injury (TRALI) is one of the leading causes of death associa-
ted with transfusion of blood and blood components. The understanding of the etiology and 
pathophysiology of this syndrome has much improved during the last decades, nevertheless 
numerous issues are still unresolved and symptomatic treatment remains the cornerstone of 
medical management. Consequently more attention is directed at primary as well as seconda-
ry prevention. The awareness of the problem within the medical society is still unsatisfactory 
which results in a high number of unrecognized cases or of inaccurate diagnoses one of which 
is cardiogenic pulmonary edema. The aim of this review is to make the TRALI syndrome more 
familiar to clinicians and to emphasize how signifi cant proper medical management is both for 
the patients presenting TRALI symptoms as well as for future recipients of blood components. 
(Cardiol J 2013; 20, 4: 337–344)
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Introduction
Since the fi rst successful blood transfusion 
performed by James Blundell in 1818, this pro-
cedure has become part of daily clinical practice. 
Advances in blood safety have greatly reduced the 
risk of transfusion-associated infectious disease 
transmission and blood has never been as safe as 
it is now, however, the risks associated with blood 
transfusion have not been entirely eliminated. 
One of them is the syndrome of acute lung injury 
(ALI) which leads to respiratory distress. This 
complication is the subject of our review. The 
first case of noncardiogenic pulmonary edema 
following transfusion was described by Bernard in 
1951 [1]. Thirty years later, Popovsky and Moore 
[2] suggested to give this complication the name 
of TRALI — transfusion-related acute lung injury. 
During the conference in Toronto in 2004, a panel 
of experts from the National Institute of Health 
fi nally established a clinical defi nition of TRALI 
based on ALI temporally associated with transfu-
sion and characterized by dyspnea, hypoxemia and 
bilateral infi ltrates on a chest X-ray [3]. This life-
-threatening reaction may be caused by any blood 
component that contains plasma [4, 5]. TRALI was 
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most frequently observed following transfusions 
of whole blood, red blood cell concentrates, fresh 
frozen plasma and platelet concentrates [5, 6]. In 
some reports the volume of plasma suffi cient to 
induce TRALI is estimated at 10–15 mL [7, 8]. The 
complication affects all age groups and occurs with 
the same frequency in both men and women [4]. 
According to the Food and Drug Administration sta-
tistics TRALI is responsible for 43% of transfusion-
-related deaths reported in 2007–2011 and it is the 
leading cause of mortality associated with this pro-
cedure [9, 10]. TRALI risk is estimated at appro-
ximately 0.02% per unit of blood component or 
0.16% per recipient [4, 11, 12]. Shaz et al. [13] esti-
mate the incidence of this syndrome at 1/260 000 
transfusions. The true TRALI prevalence rate, 
however, remains unknown due to a large number 
of cases unreported to blood transfusion centers. 
Much too often, dyspnea and hypoxia observed 
during transfusion are attributed to volume over-
load or cardiogenic pulmonary edema while mild 
cases are entirely disregarded. This precludes the 
opportunity for confi rmation of TRALI in tests as 
well as implementation of appropriate preventive 
measures.
Etiology and pathophysiology
Pathophysiology of TRALI is not fully un-
derstood. Two mechanisms which lead to the 
development of the syndrome are distinguished as 
refl ected in the following classifi cation:
 — immune-mediated TRALI, predominantly cau-
sed by anti-HLA (human leukocyte antigen) 
antibodies class I, II and/or less frequent anti-
bodies directed against specifi c antigens of gra-
nulocytes — HNA (human neutrophil antigen), 
present in the serum of the recipient or donor, 
which react with the donor’s or recipient’s 
leukocytes respectively [4, 5, 7, 12–15].
 — non-immune-mediated TRALI, which may be 
attributed to transfusion of biologically active 
compounds accumulated in stored blood com-
ponents such as bioactive lipids, proinfl amma-
tory cytokines or platelet microparticles with 
high procoagulant activity. A high potassium 
level is considered an additional risk factor 
[4, 13–20].
Leukocyte antibodies are currently believed 
to be crucial for TRALI development. The cognate 
antigens for these antibodies are human leukocyte 
antigens (either HLA or HNA) expressed on the 
recipient’s/donor’s own blood cells. The main cells 
involved in TRALI pathogenesis are neutrophils. 
The interaction between the antibody and its 
cognate antigen is thought to induce neutrophil 
activation, sequestration and fi nally, endothelial 
barrier damage. Several interesting TRALI cases 
have been reported where antibodies of one donor 
activated the leukocytes of another donor in the 
bloodstream of the recipient [21, 22]. Dykes et al. 
[23] described a case of  TRALI in a patient with 
a single lung transplant. Following transfusion of 
red blood cell concentrate the TRALI syndrome 
developed only in the transplanted organ, because 
contrary to other tissues, it contained the HLA-
-B44 antigen reactive to donor’s antibodies. This 
is strong evidence for immunological etiology of 
TRALI. Leukocyte antibodies differ as to their 
specifi city, degree of activity, as well as ability to 
induce agglutination of leukocytes. For example, 
antibodies to HNA-3a and HLA-A2 antigens which 
have proagglutination properties correlate with 
increased morbidity and mortality, whereas no 
TRALI related deaths were reported due to anti-
bodies directed against HNA-1a and HNA-2a [16].
Immune-mediated TRALI, where antibodies 
have been detected in at least one of the transfu-
sed blood components, are estimated at 65–85% 
of all reported TRALI cases [4, 5]. Cases where no 
antibodies were detected despite the manifestation 
of characteristic clinical symptoms are considered 
“non-immune-mediated” TRALI. It should also be 
noted that TRALI occurs only in some recipients 
of blood components that contain antibodies. It is 
still unclear why leukocyte antibodies cause this 
complication in some patients while not in others. 
This is usually associated with lack of cognate leu-
kocyte antigens in recipient’s/donor’s blood. These 
observations were confi rmed by the “look back” 
procedure described by Maślanka et al. [24] where 
no TRALI reaction was reported for 26 patients 
transfused with blood containing HLA antibodies 
although cognate leukocyte antigens were detec-
ted in the blood of 11/26 recipients. Previously, 
the same antibodies had caused a TRALI reaction 
in another patient. Perhaps the crucial issue here 
is the antibody titer, affi nity, avidity or density of 
cognate antigenic epitope on leukocyte cells.
However, clinical evidence indicates that most 
patients are critically ill prior to TRALI onset. 
There are additional risk factors such as mechani-
cal ventilation, sepsis, shock, hematologic malig-
nancy, surgery (e.g. cardiac, orthopedic), alcohol 
abuse and active smoking [8, 10–12]. In light of 
these observations Silliman et al. [25] postulated 
a hypothesis of a “two-hit” model. This model assu-
mes that TRALI onset depends on the coexistence 
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of a factor that predisposes a recipient’s reaction 
as well as on the presence of leukocyte-activating 
compounds in transfused blood. The “fi rst hit” 
is provoked by proinfl ammatory condition, e.g. 
pneumonia, sepsis, which induces pulmonary 
endothelial activation that promotes neutrophil 
sequestration and adhesion to pulmonary capillary 
walls. These alterations in the lung vessels are 
insuffi cient to induce TRALI but they prepare the 
ground for TRALI. The “second hit” is provided 
by transfusion of a blood component that contains 
either leukocyte antibodies or biologically active 
lipids and cytokines. These provoke neutrophil 
agglutination or induce reactive neutrophils to 
secrete proinfl ammatory mediators such as cy-
tokines (IL-1, IL-6, IL-8, TNF-alpha), release 
proteolytic enzymes (e.g. elastase, azurocidin), 
and produce reactive oxygen species [4, 16, 25]. 
This initiates the cascade of immune reactions with 
subsequent damage to the vascular endothelium 
and pulmonary capillary leakage of proteinaceous 
fl uid in the alveolar space [5, 13–15]. Additionally, 
Silliman et al. [17] demonstrate that in the “two 
hit” model leukocytes may be directly stimulated 
by biologically active substances accumulated in 
stored blood components which include: arachi-
donic acid, lyso-phosphatydylocholine (LysoPCs) 
and a soluble form of CD40 ligand (sCD40L) [5, 
13, 14]. Silliman’s observations are confi rmed by 
Covin et al. [26] who described an onset of TRALI 
in a patient after an autologous transfusion where 
no antibodies were detected in blood but leukocyte 
activation was induced by accumulation of active 
lipids. However, recent clinical observations and ex 
vivo studies question the involvement of biological-
ly active lipids and sCD40L in TRALI development 
[27–29].
According to Bux and Sachs [14], the authors of 
the threshold model for TRALI, which was presen-
ted in 2007, in the “two hit” mechanism the reaction 
occurs only if activation of neutrophils exceeds 
a critical stage. In patients with multiple risk factors 
this reaction is triggered at lower antibody titre than 
in patients with no risk factors, as each risk factor 
contributes to the reduction of the threshold of 
susceptibility to TRALI. The above hypotheses are 
not necessarily mutually exclusive but may coexist 
and present a similar clinical picture.
Clinical presentation
TRALI is characterized by acute respiratory 
failure observed during transfusion or within 
6 h of transfusion. The main symptom is dyspnea, 
which often co-occurs with tachypnea, tachycardia, 
cyanosis and frothy pulmonary secretions. Fever, 
hypotension or hypertension are also reported [6, 
25, 30]. Decreased breath sound and diffuse cra-
ckles over the lung fi elds are revealed in physical 
examination [25]. Respiratory failure is corfi rmed 
by hypoxemia (usually 30–50 mm Hg) detected in 
arterial blood gas. As these are nonspecifi c symp-
toms, TRALI recognition is based on exclusion 
of other causes such as anaphylactic reaction, 
cardiogenic pulmonary edema, acute respiratory 
distress syndrome (ARDS) or bacterial infection.
Basic laboratory tests are not considered diag-
nostic criteria, because of their low sensitivity and 
specifi city. Occasionally leukopenia, neutropenia, 
hypoalbuminemia and hypocomplementemia can 
be detected [3, 4, 6]. Although fairly typical, leu-
kopenia associated with leukocyte sequestration in 
the pulmonary circulation is usually temporary and 
often passes unnoticed [8]. Recent reports empha-
size the diagnostic signifi cance of brain natriuretic 
peptide (BNP) and it is recommended to determine 
the BNP concentration in each and every case of 
post-transfusion respiratory failure [27, 31].
TRALI frontal chest radiograph manifests 
bilateral fl uffy infi ltrations with no cardiomegaly. 
Hemodynamic monitoring helps to differentiate 
TRALI and cardiogenic pulmonary edema. Normal 
or low pulmonary capillary wedge pressure and 
central venous pressure values are characteristic 
for TRALI [4, 30].
Diagnosis
One should always suspect TRALI if dyspnea 
and hypoxia occur within a short time of transfusion 
of any blood component. During the American-
-European Consensus Conference in 2004 a group 
of experts established diagnostic criteria for TRALI 
(Table 1) [3].
A full diagnostic procedure requires that each 
TRALI case is reported to a reference center 
which performs serological testing for antibodies 
directed against HLA class I, class II, and HNA in 
recipient’s and donor’s blood. The Working Party 
on Granulocyte Immunobiology of the Internatio-
nal Society of Blood Transfusion recommends the 
lymphocytotoxicity test (LCT) for HLA antibody 
detection and one of the following tests for HLA 
non-complement binding antibodies: enzyme 
assays (ELISA — enzyme-linked immunosorbent 
assay), immunofl uorescence test or luminex tech-
nique. A combination of granulocyte immunofl uore-
scence test (GIFT) and granulocyte agglutination 
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test (GAT) is usually used for anti-HNA antibody 
detection while the positive results are verifi ed by 
monoclonal antibody immobilization of granulocyte 
antigens (MAIGA) [31, 32]. When the presence of 
antibodies in the serum of recipient/donor is confi r-
med, the subsequent step involves determination 
of the corresponding antigen in the donor/recipient 
or a cross-match between recipient’s (or donor’s) 
leukocytes and donor’s (or recipient’s) plasma. 
A positive result confi rms the diagnosis of immune-
-mediated TRALI [8, 31]. For research purposes 
the capacity of antibodies to activate leukocytes 
is sometimes measured in tests of neutrophil 
respiratory burst following incubation of plasma 
suspected of inducing TRALI with neutrophils of 
healthy people [3].
It should be emphasized that antibody detec-
tion is not indispensable for TRALI diagnosis which 
is primarily based on the clinical picture [3, 27, 33]. 
The diagnostic algorithm is presented in Figure 1.
Differential diagnosis
The criteria for TRALI diagnosis presuppose 
the exclusion of all other causes leading to acute 
respiratory distress syndrome, such as: cardiogenic 
pulmonary edema, pneumonia, bacterial contami-
nation of blood components or acute hemolytic 
reaction.
The major diffi culty remains to differentiate 
TRALI from transfusion-associated circulatory 
overload (TACO), which is a result of excessive 
volume of transfused fl uid. The clinical picture of 
TACO resembles that of cardiogenic pulmonary 
edema. Apart from dyspnea and tachypnea, the cha-
racteristic features are jugular venous distension, 
Table 1. Diagnostic criteria for transfusion-related acute lung injury (TRALI) [3, in our modification].
TRALI Possible TRALI
1. Acute lung injury: 1. Acute lung injury:
    A. Acute onset of symptoms     A. Acute onset of symptoms
    B. Hypoxemia: PaO2/FiO2 < 300 or SpO2 < 90%
        (no oxygen) or other clinical signs of hypoxemia
    B. Hypoxemia: PaO2/FiO2 < 300 or SpO2 < 90% 
        (no oxygen) or other clinical signs of hypoxemia
    C. Bilateral infiltrates on frontal chest radiograph     C. Bilateral infiltrates on frontal chest radiograph
    D. No evidence of left atrial hypertension
2. No preexisting acute lung injury before transfusion 2. No preexisting acute lung injury before transfusion
3. Development of symptoms during or within 
    6 h of transfusion
3. Development of symptoms during or within 
    6 h of transfusion
4. No temporal association with alternative risk 
    factors for acute lung injury (foreign body 
    aspiration, pneumonia, inhalation of toxins,
    burns, drowning, polytrauma, drug overdose, 
    acute pancreatitis, cardiopulmonary bypass)
4. Possible temporal association with alternative 
    risk factors for acute lung injury (foreign body 
    aspiration, pneumonia, inhalation of toxins, 
    burns, drowning, polytrauma, drug overdose, 
    acute pancreatitis, cardiopulmonary bypass)
Figure 1. Transfusion-related acute lung injury (TRALI) 
diagnostic algorithm; TACO — transfusion-associated 
circulatory overload; HLA — human leukocyte antigen; 
HNA — human neutrophil antigen; LCT — lymphocy-
totoxicity test; ELISA — enzyme-linked immunosorbent 
assay; GAT — granulocyte agglutination test, GIFT — gra-
nulocyte immunofluorescence test; MAIGA — monoclo-
nal antibody immobilization of granulocyte antigens.
www.cardiologyjournal.org 341
Krzysztof Jaworski et al., Transfusion-related acute lung injury
S3 gallop and high systolic blood pressure [3]. Gajic 
et al. [34] proposed an algorithm which is useful 
in distinguishing between these 2 conditions. It is 
based on measurement of BNP, the ratio of prote-
in concentration in the bronchial fl uid and in the 
plasma as well as the assessment of myocardial 
function. TACO as the cause of respiratory failure 
can be excluded with a high degree of probability 
when the BNP value is < 250 pg/mL or its post-
transfusion-to-pretransfusion ratio < 1.5. Index 
protein in edema fl uid/protein in serum concen-
tration < 0.65 supports the hydrostatic pulmonary 
edema, while the rate of > 0.75 indicates excessive 
endothelial barrier permeability. Fluid should be 
collected immediately after intubation, preferably 
within 15 min of the onset of symptoms, because 
if later, water is resorbed and the results of tests 
are false positive due to protein concentration in 
the alveoli [12]. When circulatory overload occurs 
the patient’s condition can rapidly be improved by 
diuretic treatment [25]. The estimated mortality 
rate is between 5–15% [34]. It should be noted that 
TACO and TRALI can coexist, moreover there is 
some evidence that TACO predisposes TRALI 
development by virtue of pro-infl ammatory effect 
of high pulmonary capillary pressure [35].
Treatment
When symptoms of acute respiratory distress 
occur during transfusion, the procedure should im-
mediately be discontinued and not resumed even if 
the symptoms diminish [36]. Treatment of TRALI 
is symptomatic and based on oxygen therapy [4, 5]. 
Approximately 70% of patients require intubation 
and mechanical ventilation [5]. The strategy of 
low tidal volumes and low plateau pressure used 
in the treatment of ARDS appears to be proper 
also for TRALI [8]. Reports of successful use of 
plasmapheresis and extracorporeal membrane 
oxygenation are rather scarce [37, 38]. There are 
numerous attempts to use glucocorticoids in cli-
nical practice but there is little scientifi c evidence 
to support this [4, 38]. The same can be said for 
the effect of inhaled nitric oxide — clinical trials 
seem to deny its potential benefi ts [39]. Another 
issue of particular signifi cance for the management 
of cardiogenic pulmonary edema, is the negative 
effect of diuretics, which might impair prognosis [4, 
38]. The role of other drugs in TRALI management 
such as synthetic surfactant is still unclear and 
requires further clinical evaluation [4].
Prognosis
Although the clinical picture of TRALI is in-
distinguishable from ALI or ARDS due to other 
than transfusion causes, the mortality rate for 
ARDS is 29–70% while for TRALI it is between 
5% and 10% [30, 35]. In 80% of cases the patient’s 
condition improves within 48–96 h while in others 
the infi ltrates in the X-ray persist and the patients 
require prolonged ventilatory support. Permanent 
lung injury is very rare [6, 39]. On the other hand, 
there is some scientifi c evidence that in patients in 
severe condition TRALI is an independent predictor 
of mortality, a prolonged hospital stay and reduced 
survival rate. It does not, however, affect the quality 
of life assessed by the SF-36 Health Survey one year 
after discharge from the hospital [40].
Prevention
As there are so few therapeutic options for 
TRALI, the importance of prevention is growing. 
Up to date, however, no consensus has been estab-
lished as to the most effective preventive strategy. 
Different countries follow different recommenda-
tions. One of the commonly accepted methods is 
deferral from donation of people immunized by 
leukocyte antigens during previous transfusions or 
pregnancy [4, 27, 32]. Various sources estimate the 
probability of immunization during transfusion at 
about 1–12% [5]. In a study involving 8,000 blood 
donors, Kakaiya et al. [41] dispute the idea of donor 
screening prior to transfusion as they found no 
statistically signifi cant difference in the incidence 
of HLA antibodies in patients previously treated 
or untreated with blood components.
Pregnancy must therefore be considered the 
main source of immunization. From 4% to 8% 
of women produce HLA antibodies during their 
fi rst pregnancy, and the probability of immuniza-
tion increases with each subsequent pregnancy, 
amounting to about 15% and 24–26% after 2 and 
3 pregnancies [24, 42]. In 2003, the English National 
Blood Service adopted the strategy of diverting plas-
ma from female donors for production of fresh froz-
en plasma which signifi cantly reduced the TRALI 
incidence rate in the UK (from 36 cases in 2003 
to 13 cases in 2009) [43, 44]. Many countries, e.g. 
France, Germany, Italy, Switzerland, USA, achieved 
similar results using the strategy for selection of 
fresh frozen plasma donors, namely the deferral 
of previously transfused patients and multiparous 
women or women with leukocyte antibodies [32]. 
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There are experts who fear that in some countries 
this strategy might cause a significant reduction 
in the number of donations (from 5% to 30%) [3, 
14, 25, 36]. On the other hand, various studies 
report that HLA antibodies are present in 1–7% 
of population that have never been subjected 
to alloexposure [5]. This phenomenon has not 
been explained yet. It is believed that the HLA 
antibodies in such patients may be autoantibodies 
or antibodies acquired as result of exposure to 
bacteria or vaccines antigens [41, 45]. Moreover, 
some people may simply be unaware of prior 
alloexposure (pregnancy ended with miscarriage 
or childhood transfusion). Prospective studies 
demonstrate that HLA antibodies rarely lead to 
the TRALI onset, therefore the deferral of all im-
munized people would contribute to unneccessary 
reduction in the number of blood donors which 
is already below demand [5]. On the other hand, 
screening of all donors for HLA antibodies would 
be a time-consuming and costly strategy as well 
as very difficult to execute.
Unlike HLA antibodies, HNA-3a antibodies 
are associated with a more severe clinical course. 
In 2008, the International Society of Blood Trans-
fusion recommended all persons with HNA-3a 
antibodies to be deferred from blood donation [5]. 
Undoubtedly the deferral from the further dona-
tion should include donors implicated in a TRALI 
case if leucocyte antibodies were detected in their 
blood [4, 5, 27]. It is therefore of extreme impor-
tance to register all suspicious cases of TRALI. 
Unfortunately, TRALI cases are still underreported 
to the blood centers which impedes testing and 
prevention. The signifi cance of the problem and 
the proper retrospective procedure that should be 
applied is described by Kopko et al. [46] in a case 
report of fatal TRALI associated with fresh frozen 
plasma transfusion from a 54-year-old multiparous 
woman, a multiple blood donor (290 donations in 
15 years). Tests performed after the tragic event 
revealed anti-neutrophil antibodies in her blood. 
A retrospective inquiry which included 73 donations 
and 36 recipients of the blood components reve-
aled that 13 of them might have had TRALI [46]. 
However, not all the cases were reported to the 
relevant authorities. The outcome of this investi-
gation clearly shows the great responsibility of the 
transfusion staff and the extent to which the fate 
of the future recipients relies on the physician’s 
decision to report the TRALI incident.
With the 2-factor etiology in mind, another po-
ssibility of TRALI prevention is the modifi cation of 
“sensitizing” factors, e.g. by applying the strategy 
of small tidal volumes in mechanically ventilated 
patients prior to elective transfusion [5].
Many countries (Poland included) try to reduce 
the incidence rate of posttransfusion immune respon-
ses by issuing for clinical use leukoreduced red blood 
cell concentrates. The process of leukoreduction 
decreases the number of leukocytes as well as the 
cytokines which they produce and this may be of 
signifi cance for recipients with HLA antibodies [5]. 
Immunized patients therefore should only be given 
leukoreducedred blood cell or platelet concentrates 
[27]. Nevertheless, studies by Silliman et al. [17] have 
demonstrated that leukoreduction does not protect 
recipients against non-immune-mediated TRALI 
because the procedure is effective for reduction of 
accumulated lipid compounds only in a small degree. 
The source of lipid compounds are platelets in case 
of LysoPCs and erythrocytes in case of 5-HETE, 
12-HETE, 15-HETE as well as arachidonic acid.
There is clinical evidence that TRALI inci-
dence is reduced by using plasma from a pool of 
500 to 1,600 donations. Leukocyte antibodies in 
such blood components are undetectable due to 
dilution and neutralization by the dissolved HLA 
antigens [5, 13].
There is ongoing research on how to improve 
the conditions in which blood components are pre-
pared and stored. In a growing number of countries, 
Poland included, the plasma volume in platelet 
concentrates is reduced and replaced by additive 
solutions such as SSP + and PAS IIIM [32]. The 
Regional Blood Transfusion Center in Warsaw is 
the only place in Poland where blood components 
are stored according to a new metod based on the 
Mirasol PRT system [47]. In the period July 2009–
–November 2011, approximately 14,500 units of 
platelet concentrates and 63,000 units of fresh 
frozen plasma were issued for clinical use and 
transfused. No TRALI reactions were observed.
TRALI recurrence is accidental or results from 
higher predisposition of the recipient. While TRALI 
incidence is estimated at 1:5000 transfusions, the 
risk of 2 episodes in the same patient with no asso-
ciated risk factors is statistically 1:25 million [48]. 
Nevertheless, some authors postulate preventive 
measures for patients with TRALI history and re-
commend to use only fresh, leukoreduced, washed 
red blood cell and platelet concentrates stored for 
less than 2 days. Such measures will contribute 
to effective reduction of TRALI risk, regardless 
of pathogenesis [48, 49].
However, the most important preventive 
measure for TRALI is the promotion of proper 
strategy for transfusion of blood components [50]. 
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Indications for transfusion should be considered 
very carefully and it should always be regarded 
only as a life-saving procedure. Transfusion of large 
numbers of red blood cell concentrates or fresh 
frozen plasma units is still common treatment for 
iron defi ciency anemia or reversal of oral anticoa-
gulation. Awareness of such transfusion-associated 
risks as TRALI, should result in more restrictive 
indications for the use of blood in clinical practice.
Conclusions
TRALI is a serious, life-threatening complica-
tion related to the transfusion of blood components. 
After years of research, the pathogenesis of the 
syndrome is better understood, the diagnostic cri-
teria have been established and preventive measu-
res implemented. This contributed to the reduction 
of the overall number of fatalities. TRALI, however, 
still remains a clinical problem. Any complication 
suspected of TRALI should immediately be re-
ported to the regional blood transfusion center, 
the diagnosis confi rmed in laboratory tests and 
the look-back procedure launched (in Poland such 
diagnostics tests are performed at the Institute of 
Hematology and Transfusion Medicine in Warsaw). 
Correct diagnosis followed by proper management 
may save the lives of our patients as well as those 
who will require blood component transfusion in 
the future.
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